These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 29406886)

  • 1. Effects of intestinal Levodopa infusion on freezing of gait in Parkinson disease.
    Zibetti M; Angrisano S; Dematteis F; Artusi CA; Romagnolo A; Merola A; Lopiano L
    J Neurol Sci; 2018 Feb; 385():105-108. PubMed ID: 29406886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Continuous Dopaminergic Stimulation on Parkinson's Disease Gait: A Longitudinal Prospective Study with Levodopa Intestinal Gel Infusion.
    Imbalzano G; Artusi CA; Ledda C; Montanaro E; Romagnolo A; Rizzone MG; Bozzali M; Lopiano L; Zibetti M
    J Parkinsons Dis; 2024; 14(4):843-853. PubMed ID: 38728203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
    Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
    Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How resistant are levodopa-resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease.
    Imbalzano G; Rinaldi D; Calandra-Buonaura G; Contin M; Amato F; Giannini G; Sambati L; Ledda C; Romagnolo A; Olmo G; Cortelli P; Zibetti M; Lopiano L; Artusi CA
    Eur J Neurol; 2023 Jan; 30(1):96-106. PubMed ID: 36093563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.
    Zibetti M; Rizzone M; Merola A; Angrisano S; Rizzi L; Montanaro E; Cicolin A; Lopiano L
    Acta Neurol Scand; 2013 May; 127(5):e28-32. PubMed ID: 23311399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 24 h Levodopa-carbidopa intestinal gel may reduce falls and "unresponsive" freezing of gait in Parkinson's disease.
    Chang FC; Tsui DS; Mahant N; Wolfe N; Kim SD; Ha AD; Drury M; Griffith JM; Fung VS
    Parkinsonism Relat Disord; 2015 Mar; 21(3):317-20. PubMed ID: 25578290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motor and non-motor outcomes in patients with advanced Parkinson's disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study.
    Lopiano L; Modugno N; Marano P; Sensi M; Meco G; Solla P; Gusmaroli G; Tamma F; Mancini F; Quatrale R; Zangaglia R; Bentivoglio A; Eleopra R; Gualberti G; Melzi G; Antonini A
    J Neurol; 2019 Sep; 266(9):2164-2176. PubMed ID: 31134377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience.
    Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M
    J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A polysomnographic study in parkinsonian patients treated with intestinal levodopa infusion.
    Zibetti M; Romagnolo A; Merola A; Priano L; Montanaro E; Angrisano S; Tribolo A; Cicolin A; Lopiano L
    J Neurol; 2017 Jun; 264(6):1085-1090. PubMed ID: 28424899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel by jejunal extension tube placement through percutaneous endoscopic gastrostomy for patients with advanced Parkinson's disease: a preliminary study.
    Zulli C; Sica M; De Micco R; Del Prete A; Amato MR; Tessitore A; Ferraro F; Esposito P
    Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2413-7. PubMed ID: 27338069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "on" freezing of gait.
    Cossu G; Ricchi V; Pilleri M; Mancini F; Murgia D; Ricchieri G; Mereu A; Melis M; Antonini A
    Neurol Sci; 2015 Sep; 36(9):1683-6. PubMed ID: 25939726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
    Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7-year experience.
    Zibetti M; Merola A; Artusi CA; Rizzi L; Angrisano S; Reggio D; De Angelis C; Rizzone M; Lopiano L
    Eur J Neurol; 2014 Feb; 21(2):312-8. PubMed ID: 24313838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
    Poewe W; Bergmann L; Kukreja P; Robieson WZ; Antonini A
    J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients.
    Sücüllü Karadağ Y; Saltoğlu T; Erdoğan Küçükdağli F; Öztürk Ö; Köseoğlu HT; Altiparmak E
    Turk J Med Sci; 2021 Feb; 51(1):84-89. PubMed ID: 32718129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.
    Fernandez HH; Standaert DG; Hauser RA; Lang AE; Fung VS; Klostermann F; Lew MF; Odin P; Steiger M; Yakupov EZ; Chouinard S; Suchowersky O; Dubow J; Hall CM; Chatamra K; Robieson WZ; Benesh JA; Espay AJ
    Mov Disord; 2015 Apr; 30(4):500-9. PubMed ID: 25545465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effect of levodopa-carbidopa intestinal gel on axial signs in Parkinson's disease.
    Fabbri M; Pongmala C; Artusi CA; Romagnolo A; Rizzone MG; Zibetti M; Lopiano L
    Acta Neurol Scand; 2019 Aug; 140(2):157-161. PubMed ID: 31025312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced therapies in Parkinson's disease: Long-term retrospective study.
    Merola A; Espay AJ; Romagnolo A; Bernardini A; Rizzi L; Rosso M; Espay KJ; Zibetti M; Lanotte M; Lopiano L
    Parkinsonism Relat Disord; 2016 Aug; 29():104-8. PubMed ID: 27215392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.